about
Current Options for the Treatment of Food AllergyClinical Management of Food Allergy.Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.Oral and sublingual immunotherapy for food allergy: current progress and future directions.Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance.Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitizationAllergist-reported trends in the practice of food allergen oral immunotherapy.Food allergies affect growth in children.Mechanisms of immune tolerance relevant to food allergyOral immunotherapy for treatment of egg allergy in children.Pathogenesis of food allergy in the pediatric patient.Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergySublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison.Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy.Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic childrenSustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.Pediatric food allergy and mucosal tolerance.Oral immunotherapy for food allergy.Egg oral immunotherapy.Oral Immunotherapy for Food Allergy.Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy.Using media messaging to promote healthful eating and physical activity among urban youth.Food-specific IgG4 is associated with eosinophilic esophagitis.Specific allergen profiles of peanut foods and diagnostic or therapeutic allergenic products.A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders.Conducting an Oral Food Challenge to Peanut in an Infant.Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial.Low dose immunotherapy in very young children to treat peanut allergy.Exploiting CD22 on antigen-specific B cells to prevent allergy to the major peanut allergen Ara h 2.Immune Mechanisms of Oral Immunotherapy.Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab.Development of a patient-centric food allergy research program: A model for action.Genetic variants at the 16p13 locus confer risk for eosinophilic esophagitisPioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune responseAnaphylaxis from peanuts ingested by blood donors?Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT)Does clinical protection persist after food allergen oral immunotherapy?
P50
Q26784498-139DC5B0-A7A3-41F6-9569-C2A52EFFB546Q30789660-47D6FA2C-A39D-4CCE-B74A-B58A3E8C9CFAQ34003041-CA2668F4-4AF0-4652-B9AC-E58A67E5886AQ34366285-F3E93AE9-9376-40C7-87C1-88E744A9D45CQ34517635-B5618765-2EBD-4DF4-AF45-7833F22A815BQ34640733-3E81A7B2-5BFD-4D49-8E8E-53B4A7AE9B3DQ34924746-BE47A0FA-8F26-41F0-A353-85A40BFBB101Q34925031-BCA4545D-388E-4685-BBD6-361F47A30716Q35599989-E288CD64-CB82-4361-8415-E7494E5E2BE1Q36180099-656E9602-0FD2-4AE4-98D5-88C2C5031ABEQ36385056-07DA5EAE-B746-498E-882C-A0DBAA0676A0Q36520518-54FABF46-8F0D-43A6-962F-F3C28465E06FQ37067516-5EF6270C-AB66-4ED9-A054-5F37E42E7E98Q37149492-1E1C3747-8A80-438A-B68C-CD55D406F1D1Q37188523-ED0EFBBF-B2D5-4A87-B348-10D55AE6AA57Q37649825-C5BDDCC1-07EA-4DCC-B0CC-F97CC2878B43Q37761046-4BF58F9F-CFC2-4CC4-A354-D0248A900286Q37790238-84674E84-8343-4802-AD35-293F78E93E7AQ38001296-90D55EA0-840E-47ED-BE7F-302DF807F6A9Q38652624-2261ECA9-5D98-420F-B6E7-7245054BD848Q38890046-2DCDB957-3361-4B15-B5AB-F1DDFB774ABCQ39408623-963404DE-42D4-4D46-8AF9-A3FCBF8E7CC6Q39716172-707F0CF4-F519-4587-B6E9-0F9D9F0FD7ADQ41645197-515F35E5-E039-4AA4-97E0-F7D5053725E7Q45063345-D261E29F-4A9A-4907-BCA7-CA2D43BE4EF4Q45064623-91A6EA39-BC35-4FCE-B1E2-8CED32A574AFQ46094708-7DE7706D-F798-4A58-B83F-12D9262118E0Q46095582-516EABC8-2C81-4451-8A3E-A56798AFC8B2Q46462559-7D25BDF4-F266-46E5-B3E5-96A5F1D249D0Q47146910-FB6867ED-1BAB-4441-A3B0-0ABC8C0A3456Q47759023-7504C014-666D-40FE-A852-5ACE9E496F78Q49183777-6694F441-AFCA-415D-B8B4-524F7CFE3D02Q50326807-733481AE-410F-44D6-901B-7907A4789CF9Q52602562-DE88A151-0787-4557-92CA-09F21125C87BQ57329659-099D1646-24A9-4EC3-994E-27167DE1D78DQ82906400-60A1D1C7-9753-4BF8-B7CB-782C17F99A57Q84861865-EE005AEE-3D4A-4299-814E-0DD847A0F1F6Q85516621-09385F66-9B0A-4F9A-A721-0D6AD1353901Q86018341-F2C8ADF8-CB6C-446C-9969-91633CD7DC93
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Brian P. Vickery
@ast
Brian P. Vickery
@en
Brian P. Vickery
@es
Brian P. Vickery
@nl
Brian P. Vickery
@sl
type
label
Brian P. Vickery
@ast
Brian P. Vickery
@en
Brian P. Vickery
@es
Brian P. Vickery
@nl
Brian P. Vickery
@sl
prefLabel
Brian P. Vickery
@ast
Brian P. Vickery
@en
Brian P. Vickery
@es
Brian P. Vickery
@nl
Brian P. Vickery
@sl
P106
P1153
26659304100
P21
P31
P496
0000-0002-7243-5543